Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Gilteritinib Formulations in Healthy Subjects
NCT03964038Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gilteritinib in acute myeloid leukemia (AML) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-Time Curve from Dosing to 72 Hours, Area Under the Concentration-Time Curve from Dosing Extrapolated to Infinity and 2 more. Started May 2019; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03964038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964038.